Donepezil Global Market Report 2025

The donepezil market size has grown strongly in recent years. It will grow from $1.0 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period was driven by the increasing prevalence of Alzheimer's disease, a growing geriatric population, rising government spending and support programs, greater awareness of neurodegenerative disorders, and the increasing demand for high-quality nucleic acid samples.

The donepezil market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The projected growth during the forecast period is driven by rising healthcare expenditure, a greater emphasis on early diagnosis of Alzheimer's disease, increasing demand for combination therapies, expanding investment in healthcare infrastructure, and growing awareness of neurodegenerative illnesses. Key trends include innovations in drug formulations and delivery methods, technological advancements, the introduction of novel dosage forms, the approval of generic versions of donepezil, and the development of advanced research facilities.

The increasing prevalence of Alzheimer's disease is expected to drive the growth of the donepezil market. Alzheimer's disease is a progressive neurological disorder that leads to brain cell degeneration and death, resulting in memory loss, cognitive decline, and behavioral changes. The rise in Alzheimer's cases is attributed to factors such as an aging population, population growth, lifestyle-related risks, the increase in chronic diseases, genetic predisposition, and environmental exposures. Donepezil plays a crucial role in managing Alzheimer's symptoms by improving cognitive function and daily living abilities through its effect on acetylcholine levels in the brain. For instance, in May 2024, a report by the Alzheimer’s Association, a US-based nonprofit dedicated to Alzheimer's care, support, and research, indicated that the number of Americans aged 65 and older diagnosed with Alzheimer's dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the rising incidence of Alzheimer's disease is fueling the expansion of the donepezil market.

Leading companies in the donepezil market are focusing on developing innovative technologies such as advanced transdermal systems to enhance patient compliance and treatment effectiveness through extended-release formulations. The donepezil system refers to the pharmacological mechanism of action of donepezil, a medication primarily used for treating Alzheimer's disease and other forms of dementia. For instance, in October 2022, Corium Innovation Inc., a US-based biopharmaceutical company, launched the donepezil transdermal system (Adlarity) for treating patients with mild, moderate, or severe Alzheimer’s disease dementia. This transdermal formulation delivers donepezil directly through the skin, bypassing the digestive system, thereby reducing gastrointestinal side effects and offering a more convenient administration method. This innovation benefits both Alzheimer’s patients and their caregivers by improving adherence to treatment.

In August 2023, Corium Innovation Inc. partnered with Lotus Pharmaceuticals to expand the availability of ADLARITY® in multiple Asian markets. The partnership includes a license agreement for ADLARITY, an innovative donepezil transdermal system for treating Alzheimer’s dementia, across ten markets in Asia. Lotus Pharmaceuticals, a Taiwan-based pharmaceutical company, specializes in commercializing both novel and generic pharmaceuticals, helping to bring advanced Alzheimer’s treatments to a broader global population.

Major players in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy's Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group.

North America was the largest region in the donepezil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in donepezil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the donepezil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Donepezil is a medication used to manage symptoms of Alzheimer's disease by preventing the breakdown of acetylcholine, a neurotransmitter essential for memory and cognition. As a cholinesterase inhibitor, it enhances cognitive function and helps slow symptom progression in patients with mild to moderate Alzheimer's disease.

The primary dosage forms of donepezil include 5 mg, 10 mg, and 23 mg. The 5 mg dosage specifically refers to donepezil hydrochloride, commonly prescribed for treating dementia associated with Alzheimer's disease. It is administered through various routes, such as oral and transdermal, and is utilized across multiple settings, including hospitals, clinics, and drugstores.

The donepezil market research report is one of a series of new reports that includes donepezil market statistics, including donepezil industry global market size, regional shares, competitors with a donepezil market share, detailed donepezil market segments, market trends and opportunities, and any further data you may need to thrive in the donepezil industry. This donepezil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The donepezil market consists of sales of orally disintegrating tablets, experimental and niche products, active pharmaceutical ingredients, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.